Alnylam begins dosing in Phase We clinical trial with ALN-TTRsc for treatment of ATTR Alnylam Pharmaceuticals, Inc erectile dysfunction . , a respected RNAi therapeutics company, announced today that it provides initiated dosing in its Phase I scientific trial with ALN-TTRsc, an RNAi therapeutic targeting transthyretin for the treating TTR-mediated amyloidosis . ATTR is caused by mutations in the TTR gene which trigger abnormal amyloid proteins deposits to accumulate in a variety of tissues including peripheral nerves and center, leading to neuropathy and/or cardiomyopathy.
This content was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health Information, an unbiased news service editorially, is a scheduled plan of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente. Â.. 1 in 5 people infected with swine flu during 1st yr of epidemic, WHO-led research shows At least one in five people worldwide were infected with swine flu during the first yr of the 2009-2010 H1N1 pandemic, on Friday an international research group said, but the death count was just 0.02 %, Reuters reports .